Serotonin Transporter Gene Promotor Polymorphism (5-HTTLPR) Associations with Number of Psychotropic Medication Trials in a Tertiary Care Outpatient Psychiatric Consultation Practice

Psychosomatics

Volumn 52, Issue 2, 2011, Pages 147-153

  Rundell, James R ^a,b   Staab, Jeffrey P ^a,b   Shinozaki, Gen ^a,b   McAlpine, Donald ^a,b  

^a MAYO CLINIC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN TRANSPORTER; PSYCHOTROPIC AGENT; SLC6A4 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSULTATION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; GENERALIZED ANXIETY DISORDER; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; INDEPENDENT LIVING; MALE; MENTAL PATIENT; OUTPATIENT CARE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATOFORM DISORDER; TERTIARY HEALTH CARE; AGED; ALLELE; CHI SQUARE DISTRIBUTION; GENETIC POLYMORPHISM; GENETICS; MENTAL DISEASE; MIDDLE AGED; PHARMACOGENETICS; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; CHI-SQUARE DISTRIBUTION; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MENTAL DISORDERS; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 79958177106     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2010.12.013     Document Type: Article

References (25)

1. Mrazek D. Psychiatric Pharmacogenomics 2010, Oxford University Press, New York.
2. Paulose-Ram R., Safran M.A., Jonas B.S., et al. Trends in psychotropic medication use among US adults. Pharmacoepidemiol Drug Saf 2007, 16:560-570.
3. Merikangas K.R., Risch N. Will the genomics revolution revolutionize Psychiatry?. Am J Psychiatry 2003, 160:625-635.
4. Rundell JR, Staab JP: Management recommendation impacts of pharmacogenomic testing in a tertiary care outpatient psychosomatic medicine practice. Psychosomatic Medicine, in press.
5. Mrazek D.A., Rush A.J., Biernacka J.M., et al. 5-HTTLPR Variation and Citalopram Response. Neuropsychiat Genet 2009, 150B:341-351.
6. Kohen R., Cain K.C., Mitchell P.H., et al. Association of serotonin transporter gene polymorphisms with poststroke depression. Arch Gen Psychiatry 2008, 65:1296-1302.
7. Henningsen P., Zimmermann T., Sattel H. Medically unexplained physical symptoms, anxiety, and depression: A meta-analytic review. Psychosom Med 2003, 65:528-533.
8. Rundell J.R., Amundsen K., Rummans T.L., et al. Toward defining the scope of psychosomatic medicine practice: Psychosomatic Medicine in an outpatient tertiary care practice setting. Psychosomatics 2008, 49:487-493.
9. Guthrie E. Medically unexplained symptoms in primary care. Adv Psychiatr Treatment 2008, 14:432-440.
10. Rundell J.R., Staab J.P., Shinozaki G., et al. Pharmacogenomic testing in a tertiary care outpatient psychosomatic medicine practice. Psychosomatics 2011, 52:141-146.
11. Murphy D.L., Lerner A., Rudnick G., et al. Serotonin transporter: Gene, genetic disorders, and pharmacogenetics. Mol Interv 2004, 4:109-123.
12. Seretti A., Mandelli L., Lorenzi C., et al. Serotonin transporter gene influences the time course of improvement of core depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Research 2007, 149:185-193.
13. Lesch K.P., Bengel D., Heils A., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996, 274:1527-1531.
14. Caspi A., Sugden K., Moffitt T.E. Influence of life stress on depression: Moderation of a polymorphism in the 5-HTT Gene. Science 2003, 301:386-389.
15. Lin E., Chen P.S. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 2008, 9:935-946.
16. Serretti A., Kato M., DeRonchi D., et al. Meta-analysis of serotonin transporter gene polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007, 12:247-257.
17. Beck A.T., Steer R.A., Brown G.K. Manual: Beck Depression Inventory 1996, The Psychological Corporation, San Antonio, TX. 2nd ed.
18. Beck A.T., Epstein N., Brown G., et al. An inventory for measuring clinical anxiety-psychometric properties 1998, The Psychological Corporation, San Antonio, TX.
19. Kroenke K., Spitzer R.L., Williams J.B.W. The PHQ-9: Validity of a brief depression severity measure. J Gen Internal Med 2001, 16:606-613.
20. Babor T.F., de la Fuente J.R., Saunders J., et al. The Alcohol Use Disorders Identification Test-Guidelines for use in primary health care 1992, World Health Organization, Geneva Switzerland.
21. Lecrubier D.V., Sheehan E., Weiller P. The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and validity according to the CIDI. Eur Psychiatry 1997, 12:224-231.
22. Gelenter J., Cubells J.F., Kidd J.R. Population studies of polymorphisms of the serotonin transporter gene. Am J Med Genet 1999, 88:61-66.
23. Serretti I., Artioli P., Quartesan R. Pharmacogenetics in the treatment of depression: Pharmacodynamic studies. Pharmacogenet Genom 2005, 15:61-67.
24. Smits K.M., Smits L.J., Schouten J.S., et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: A systematic review. Mol Psychiatry 2004, 9:433-441.
25. Sullivan P.F. Spurious genetic associations. Biol Psychiatry 2007, 61:1121-1126.